BusinessWire Press Release
FARGO, N.D. — October 22, 2025 — CorVent Medical, Inc., an innovative medtech
company applying artificial intelligence (AI) and machine learning (ML) to improve outcomes
for critically ill, ventilated patients, today announced the launch of its CorVision™ intelligent
ventilation software platform and the opening of its Series B financing round.
Following the commercial success of its RESPOND™ ventilator and more than $45 million
raised through Series A, CorVent is now expanding its AI/ML platform strategy, supported by
proceeds from the upcoming Series B, to advance critical care decision-making and drive
efficiency across intensive care and emergency settings. The company plans to submit a
510(k) application to the U.S. Food and Drug Administration in November 2025, marking a
significant milestone in the expansion of its digital respiratory care portfolio.
CorVent has engaged Burns McClellan, Inc. as its investor relations and strategic
communications advisor to support its growth initiatives and capital market activities. In
connection with the Series B, CorVent executives will attend the J.P. Morgan Healthcare
Conference in January 2026 and are currently scheduling meetings with investors and
strategic partners.
“Critical care teams today face an unprecedented combination of clinical complexity, staffing
shortages, and rising patient acuity. With CorVision™, we are applying advanced predictive
intelligence to make ventilation management safer, more efficient, and more accessible
especially in rural and resource-limited healthcare environments.” said Richard Walsh, Chief
Executive Officer of CorVent Medical.
The CorVision™ SaaS platform integrates seamlessly with hospital EMR systems,
telemedicine networks, and rural health infrastructures, enabling scalable solutions that
strengthen healthcare system resilience and improve ventilator management at the bedside
and beyond.
About CorVent Medical
CorVent Medical, Inc. is a U.S.-owned and operated medical technology company
transforming respiratory care through innovation that is Simple, Safe, and Smart. Founded
in 2020 to address the growing need for adaptable and affordable ventilatory support, CorVent
combines clinical expertise with AI/ML driven insights to optimize healthcare outcomes for
critically ill patients in both urban and rural settings.
CorVent Medical
Media Contact: Tiffany Wirth, CMO
Email: twirth@corventmedical.com
Burns McClellan for CorVent
Investor Relations
Contacts: Lee Roth / Joseph Green / Eric Ando
Email: lroth@burnsmc.com / jgreen@burnsmc.com / eando@burnsmc.com
Phone: 646-930-4406
